论文部分内容阅读
目的分析PBK在前列腺癌中的表达及临床意义。方法利用前列腺癌的组织芯片,包含98例前列腺癌及81例对照癌旁组织作为研究对象,免疫组化方法检测PBK的表达情况,并运用统计学方法分析免疫组化芯片及Taylor数据库中PBK表达与前列腺癌临床病理特征之间的关系。结果 PBK在前列腺癌中表达明显升高(P=0.001);且在Gleason高评分组的表达比低评分组表达升高(P=0.001)。Taylor数据库得到相似结果,且运用Kaplan-Meier分析发现PBK与无生化复发生存率显著相关(P=0.007),最后采用Cox回归模型进行多因素综合分析发现在影响前列腺癌预后的队列中,PBK高表达(P=0.041)与Gleason评分、病理分期都是前列腺癌生化复发的独立预测指标。结论 PBK的表达与前列腺癌密切相关,可作为临床诊断及治疗的分子标志物。
Objective To analyze the expression and clinical significance of PBK in prostate cancer. Methods Tissue microarray of prostate cancer including 98 cases of prostate cancer and 81 cases of paracancerous tissues was used as the research object. The expression of PBK was detected by immunohistochemical method. The expression of PBK in immunohistochemistry chip and Taylor database was analyzed by using statistical methods And the clinicopathological features of prostate cancer. Results The expression of PBK in prostate cancer was significantly increased (P = 0.001). The expression of PBK in the Gleason high score group was higher than that in the low score group (P = 0.001). Similar results were obtained from the Taylor database, and Kaplan-Meier analysis showed significant correlations between PBK and non-biochemical recurrence (P = 0.007). Finally, a Cox regression model was used for multivariate analysis to find that in the cohort that affects the prognosis of prostate cancer, PBK Expression (P = 0.041), Gleason score and pathological stage were all independent predictors of biochemical recurrence of prostate cancer. Conclusion The expression of PBK is closely related to prostate cancer and can be used as a molecular marker for clinical diagnosis and treatment.